SCHEMBL1424040

SCHEMBL1424040

Cc1ncn(C(c2ccccc2)(c2ccccc2)c2ccccc2)c1C(=O)c1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.47
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
CNR2 P34972 7/20 0.40
CNR1 P21554 5/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPT P10636 2/20 0.39
NR1I2 O75469 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423435 0.83 CDC25B (0.47) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL2203211 0.75 CDC25B (0.49) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL643241 0.74 TRPM8 (0.38) ALDH1A1KMT2AMEN1HTTPLK1
SCHEMBL9656194 0.74 CYP1B1 (0.44) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL9657375 0.74 NR4A1 (0.34) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL9656211 0.74 CYP1B1 (0.44) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL2203209 0.72 CDC25B (0.46) CDC25BNR4A1NR4A2NR4A3CNR2
SCHEMBL1423385 0.71 CYP2C19 (0.42) ALDH1A1HPGDKDM4ECYP1A2TSHR
SCHEMBL2453942 0.71 TSHR (0.44) ALDH1A1HPGDKDM4EKMT2ACYP1A2
SCHEMBL8499951 0.70 KCNN4 (0.36) ALDH1A1HPGDKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258167-B2 Naphthylmethylimidizoles as therapeutic agents ALLERGAN, INC (US) 2012-09-04 US disclosed
US-8013169-B2 Naphthylmethylimidizoles as therapeutic agents ALLERGAN, INC (US) 2011-09-06 US disclosed
EP-2296648-A1 NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE Allergan, Inc. (US) 2011-03-23 EP disclosed
WO-2009140137-A9 NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE ALLERGAN, INC. (US) 2010-03-18 WO disclosed
US-20100004305-A1 NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. 2010-01-07 US disclosed
WO-2009140137-A1 NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE ALLERGAN, INC. (US) 2009-11-19 WO disclosed
US-20090286842-A1 NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2009-11-19 US disclosed
WO-2008086131-A1 NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALLERGAN, INC. (US) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286842-A1 NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS NQO1, HNMT, ALPI CDC25B 1619/4885NR4A1 2958/4885NR4A2 2595/4885
US-20100004305-A1 NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS ALPI, ALPP, NCL CDC25B 1277/4885NR4A1 982/4885NR4A2 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.